Wall Street Zen Upgrades Establishment Labs (NASDAQ:ESTA) to Hold

Key Points

• Wall Street Zen upgraded Establishment Labs from a "sell" rating to a "hold" rating, reflecting changing market sentiments toward the stock.
• Establishment Labs has a consensus rating of "Moderate Buy" and an average price target of $56.50, while having mixed reviews from other analysts.
• The company reported a quarterly revenue of $51.30 million but posted a loss of ($0.57) earnings per share, missing earnings estimates.

Establishment Labs (NASDAQ:ESTA - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Sunday.

Several other research firms also recently weighed in on ESTA. Canaccord Genuity Group began coverage on Establishment Labs in a research note on Wednesday, August 20th. They set a "buy" rating and a $60.00 price target for the company. Mizuho raised their target price on Establishment Labs from $58.00 to $70.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 16th. Weiss Ratings restated a "sell (d-)" rating on shares of Establishment Labs in a research note on Wednesday, October 8th. Finally, Citigroup restated a "neutral" rating on shares of Establishment Labs in a research note on Tuesday, October 7th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Establishment Labs has a consensus rating of "Moderate Buy" and an average price target of $56.50.

Establishment Labs Stock Up 1.4%

ESTA stock opened at $47.26 on Friday. The company has a debt-to-equity ratio of 9.71, a quick ratio of 1.67 and a current ratio of 2.84. The company has a market capitalization of $1.37 billion, a price-to-earnings ratio of -15.50 and a beta of 0.85. Establishment Labs has a fifty-two week low of $26.56 and a fifty-two week high of $50.85. The stock has a fifty day moving average of $40.10 and a 200-day moving average of $38.17.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.03). The firm had revenue of $51.30 million for the quarter, compared to the consensus estimate of $50.80 million. Establishment Labs had a negative return on equity of 224.34% and a negative net margin of 49.89%.The firm's revenue was up 16.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.62) EPS. Establishment Labs has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Establishment Labs will post -2.41 earnings per share for the current year.

Institutional Trading of Establishment Labs

Several institutional investors and hedge funds have recently modified their holdings of the business. ANTIPODES PARTNERS Ltd purchased a new position in shares of Establishment Labs during the 1st quarter valued at about $81,000. Osaic Holdings Inc. increased its stake in Establishment Labs by 900.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company's stock worth $85,000 after purchasing an additional 1,800 shares during the period. CWM LLC increased its stake in Establishment Labs by 45.9% in the 2nd quarter. CWM LLC now owns 2,182 shares of the company's stock worth $93,000 after purchasing an additional 686 shares during the period. Brian Low Financial Group LLC purchased a new position in Establishment Labs in the 3rd quarter worth approximately $223,000. Finally, Patriot Financial Group Insurance Agency LLC grew its position in shares of Establishment Labs by 5.2% in the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 6,025 shares of the company's stock worth $257,000 after buying an additional 300 shares during the last quarter. Hedge funds and other institutional investors own 72.91% of the company's stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.